I'm LongbridgeAI, I can summarize articles.SSY Group has obtained China NMPA production registration approval for its vitamin K1 injection (1 ml: 10 mg). Classified as a Category 3 chemical drug, this product is treated as having passed the consistency evaluation. This approval expands SSY Group's portfolio of injectable drugs.
- SSY Group received China NMPA production registration approval for vitamin K1 injection (1 ml: 10 mg). * Classed as a Category 3 chemical drug, treated as having passed consistency evaluation. * Approval expands the group’s injectable drugs portfolio. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260820-12291962), on August 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)